In December 1996, 8 days before Christmas, the US Food and Drug Administration (FDA) approved Lipitor (atorvastatin; Pfizer) for the treatment of hyperlipidemia. Lipitor would become one of the most profitable prescription drugs in history, bringing in $130 billion in sales during its lifetime as a brand-name product and peaking at nearly $13 billion in sales in 2006 alone.1-3 Lipitor was far from the first statin in its class (simvastatin, pravastatin, and fluvastatin were already on the market), but 1996 was also the year that the FDA began allowing direct-to-consumer broadcast advertising. Lipitor was aggressively marketed based on its more potent lowering of cholesterol levels compared with other statins.1
Gellad WF, Good CB. Prescription of Brand-Name Medications When Generic Alternatives Are Available—Patently Unfair. JAMA Intern Med. 2016;176(9):1323–1324. doi:10.1001/jamainternmed.2016.3389
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: